ELYM Eliem Therapeutics Inc

Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024.

Stifel 2024 Virtual Immunology and Inflammation SummitDate: Wednesday, September 18, 2024Format: 1x1 meetings

About Eliem Therapeutics, Inc.Eliem Therapeutics is focused on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia and membranous nephropathy. For more information, please visit https://eliemtx.com/.

InvestorsChris Brinzey ICR Westwickechris.brinzey@westwicke.com339-970-2843